1 / 5

New Guidelines for Myocardial Ischemia Management

New Guidelines for Myocardial Ischemia Management. AHA Scientific Statement: Pharmacologic treatment of hypertension in stable angina. I. IIa. IIb. III. A. β-blocker (prior MI), ACEI/ARB (diabetes and/or LV dysfunction), and diuretic

egans
Télécharger la présentation

New Guidelines for Myocardial Ischemia Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Guidelines for Myocardial Ischemia Management

  2. AHA Scientific Statement: Pharmacologic treatment of hypertension in stable angina I IIa IIb III A β-blocker (prior MI), ACEI/ARB (diabetes and/or LV dysfunction), and diuretic If β-blocker contraindicated or side effects occur, substitute a nonDHP CCB Add long-acting DHP CCB to β-blocker, ACEI/ARB, diuretic regimen if angina or BP remains uncontrolled Target BP is <130/80 mm Hg or <120/80 mm Hg if LV dysfunction is present B B B Rosendorff C et al. Circulation. 2007;115:2761-88.

  3. BP <120/80 mm Hg LDL-C <100 mg/dL Antiplatelet therapy β-Blocker ACEI or ARB A1C <7% Aldosterone blocker (select women) Smoking cessation Heart-healthy eating pattern Regular physical activity Weight management CVD prevention in high-risk women: Class I recommendations Mosca L et al. Circulation. 2007;115:1481-1501.

  4. CVD prevention in high-risk women: Class II recommendations Consider • LDL-C <70 mg/dL (very-high-risk women) • HDL/non-HDL therapy • Omega-3 fatty acid supplementation • Depression referral and treatment Mosca L et al. Circulation. 2007;115:1481-1501.

  5. Optimal patient care in stable CAD: Summary • Establish aggressive treatment goals • Utilize intensive, multifaceted therapy to achieve and maintain treatment goals • Lifestyle modification • Risk factor reduction • Antianginal therapy

More Related